Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | MMP13 | P45452 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CRHBP | P24387 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179082 | 0.88 | HPGD (0.73) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL179025 | 0.86 | HPGD (0.84) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5820481 | 0.85 | HPGD (0.68) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1709310 | 0.85 | HPGD (0.73) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3567133 | 0.85 | HPGD (0.68) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL179085 | 0.84 | RAB9A (0.76) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL108701 | 0.84 | KMT2A (0.73) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2937877 | 0.83 | SMN1; SMN2 (0.70) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5191510 | 0.82 | HSD17B10 (0.69) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29196210 | 0.82 | HPGD (0.70) | HPGDHSD17B10NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478653-B1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2014-07-02 | — | — | EP | claimed |
| US-6995143-B2 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2006-02-07 | — | — | US | claimed |
| US-20030212011-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-11-13 | — | — | US | claimed |
| EP-1478653-B1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009045761-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | ABSOLUTE SCIENCE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2006093518-A2 | THIENYL COMPOUNDS FOR TREATING VIRUS-RELATED CONDITIONS | APATH, LLC (US) | 2006-09-08 | — | — | WO | disclosed |
| US-6995143-B2 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2006-02-07 | — | — | US | disclosed |
| EP-1478653-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2004-11-24 | — | — | EP | disclosed |
| US-20030212011-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-11-13 | — | — | US | disclosed |
| WO-2003072588-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212011-A1 | Macrolides with antibacterial activity | MRPL21, RPS21, MRPS18A | HPGD 4573/4885HSD17B10 612/4885NPC1 133/4885 |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | HPGD 194/4885HSD17B10 476/4885NPC1 428/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | HPGD 599/4885HSD17B10 1348/4885NPC1 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.